Abstract
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been shown to associate with these TFs and contribute to aggressive cancers including prostate cancer (PC). Here, we show that chromatin accessibility defines castration-resistant prostate cancer (CRPC). We show that the deregulation of androgen receptor (AR) expression is a driver of chromatin relaxation and that AR/androgen-regulated bromodomain-containing proteins (BRDs) mediate this effect. We also report that BRDs are overexpressed in CRPCs and that ATAD2 and BRD2 have prognostic value. Finally, we developed gene stratification signature (BROMO-10) for bromodomain response and PC prognostication, to inform current and future trials with drugs targeting these processes. Our findings provide a compelling rational for combination therapy targeting bromodomains in selected patients in which BRD-mediated TF binding is enhanced or modified as cancer progresses.
Original language | English (US) |
---|---|
Pages (from-to) | 2045-2059 |
Number of pages | 15 |
Journal | Cell reports |
Volume | 19 |
Issue number | 10 |
DOIs | |
State | Published - Jun 6 2017 |
Keywords
- ATAD2
- BRD2
- BRD4
- BROMO-10
- androgen receptor
- bromodomain inhibitor
- castration-resistant prostate cancer
- chromatin
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)